


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Ashkenazi et al.
Appl. No. : 09/978,193
Filed : October 15, 2001
For : SECRETED AND
TRANSMEMBRANE
POLYPEPTIDES AND
NUCLEIC ACIDS
ENCODING THE SAME
Examiner : Unknown
Group Art Unit : Unknown

I hereby certify that this correspondence and all
marked attachments are being deposited with the
United States Postal Service as first class mail in an
envelope addressed to: Commissioner for Patents,
Washington, D.C. 20231, on

February 11, 2002
(Date)


Ginger R. Dreger, Reg. No. 33,055

TRANSMITTAL LETTER

COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231


Dear Sir:


Enclosed for filing in the above-identified application is the following:

- (X) Amendment
- (X) Sequence Submission Statement in 429 pages;
- (X) Substitute Sequence Listing in computer readable form;
- (X) Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410; and

- (X) A return prepaid postcard.


Ginger R. Dreger
Registration No. 33,055
Attorney of Record



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/978,193	10/15/2001	Avi J. Ashkenazi	P2630P1C6

CONFIRMATION NO. 4687

FORMALITIES LETTER



OC000000007180950

Ginger R. Dreger, Esq.
Knobbe Martens Olson & Bear
Suite 1150
201 California Street
San Francisco, CA 94111

Date Mailed: 12/11/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Ashkenazi et al.
 Appl. No. : 09/978,193
 Filed : October 15, 2001
 For : SECRETED AND
 TRANSMEMBRANE
 POLYPEPTIDES AND NUCLEIC
 ACIDS ENCODING THE SAME
 Examiner : Unknown

) Group Art Unit Unknown

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on

February 11, 2007
(Date)

Ginger R. Dreger, Reg. No. 33,055

SEQUENCE SUBMISSION STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Dear Sir:

This is in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed December 11, 2001. I hereby state that the amendments, made in accordance with 37 C.F.R. § 1.825(a) and included in the Substitute Sequence Listing submitted herewith, are supported in the application, and that the Substitute Sequence Listing does not include new matter.

that the information recorded in the currently submitted substitute copy of the paper form of the Sequence Listing

I further state that the information recorded in the currently submitted substitute copy of the computer-readable form of the Sequence Listing is identical to the paper form of the Sequence Listing submitted herewith as required in 37 C.F.R. § 1.825(b).

computer-readable form.
submitted herewith as required in 37 C.F.R. § 1.825(b).

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,
MARTENS OLSON & BEAR, LLP

Respectfully submitted,

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: February 11, 2002

By:

Ginger R. Dreger
Registration No. 33,055
Attorney of Record
620 Newport Center Drive, 16th Floor
Newport Beach, CA 92660
(415) 954-4114